EL7.AI
Stocks•31 July 2026•
1 min read

SDEV and NVNO Report Q2 Results with Key Operational and Regulatory Milestones

Key Facts

1Stablecoin Development Corporation reported $2.2 million in staking revenue for Q2 and grew its SKY position to 2.29 billion tokens.
2enVVeno Medical received FDA IDE approval for a pivotal trial of its non-surgical venous valve, with cash runway extending into Q3 2027.

In a move reflecting the evolving landscapes of digital assets and medical technology, Stablecoin Development Corporation and enVVeno Medical reported their Q2 2026 financial results. Stablecoin Development (SDEV) generated $2.2 million in staking revenue and expanded its SKY token position to 2.29 billion tokens. Simultaneously, enVVeno Medical (NVNO) achieved a major regulatory milestone by receiving FDA IDE approval for a pivotal trial of its non-surgical venous valve, supported by a cash runway extending into the third quarter of 2027.

These results arrive as investors scrutinize the cash sustainability of small-cap entities, with NVNO reporting a 46% year-over-year reduction in net loss. According to market data, SDEV's strategic focus on the Sky Protocol strengthens its foothold in the stablecoin economy, while NVNO maintains disciplined capital management with total cash and investments reaching $21.5 million as of June 30, 2026.

Traders should monitor upcoming catalysts in the US economic calendar, including the CB Consumer Confidence index on July 28, which may influence broader market sentiment for growth-oriented small-cap stocks.